Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The development of osteosarcoma, the most common malignant primary bone tumor is characterized by a vicious cycle established between tumor proliferation and paratumor osteolysis. This osteolysis is mainly regulated by the receptor activator of nuclear factor κB ligand (RANKL). Preclinical studies have demonstrated that Rankl blockade by soluble receptors is an effective strategy to prevent osteolytic lesions leading to osteosarcoma inhibition. A new therapeutic option could be to directly inhibit Rankl expression by small interfering RNAs (Rkl-siRNAs) and combine these molecules with chemotherapy to counteract the osteosarcoma development more efficiently. An efficient siRNA sequence directed against both mouse and rat mRNAs coding Rankl was first validated in vitro and tested in two models of osteosarcoma: a syngenic osteolytic POS-1 model induced in immunocompetent mice and a xenograft osteocondensant model of rat OSRGA in athymic mice. Intratumor injections of Rankl-directed siRNAs in combination with the cationic liposome RPR209120/DOPE reduced the local and systemic Rankl production and protected bone from paratumor osteolysis. Although Rkl-siRNAs alone had no effect on tumor development in both osteosarcoma models, it significantly blocked tumor progression when combined with ifosfamide compared with chemotherapy alone. Our results indicate that siRNAs could be delivered using cationic liposomes and thereby could inhibit Rankl production in a specific manner in osteosarcoma models. Moreover, the Rankl inhibition mediated by RNA interference strategy improves the therapeutic response of primary osteosarcoma to chemotherapy. © 2011 American Society for Bone and Mineral Research
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rational siRNA design for RNA interference
Reynolds, A., Leake, D., Boese, Q., Scaringe, S., Marshall, W. S., & Khvorova, A. (2004) · Nature Biotechnology · doi:10.1038/nbt936 · Cited by 2,094 · cited 1×
“Following the guideline of Reynolds and colleagues,((33)) two customer-specified siRNAs were designed to inhibit both mouse and rat Rankl gene expression by targeting two 19-nucleotide mRNA sequences starting at positions 749 and 795 in Mus musculus gene (NM_011613).”
MethodRegulation of cancer cell migration and bone metastasis by RANKL.
Jones, D. H., Nakashima, T., Sanchez, O. H., Kozieradzki, I., Komarova, S. V., Sarosi, I., Morony, S., Rubin, E., Sarao, R., Hojilla, C. V., et al. (2006) · Nature · doi:10.1038/nature04524 · Cited by 796 · cited 2×
“(16) Specific neutralization of RANKL has been achieved by either soluble RANK-IgG-Fc,(17) recombinant OPG,(18) or OPG-like peptidomimetic administrations(19) in various preclinical models of osteolytic diseases and in osteosarcoma models.”
MethodCommon Musculoskeletal Tumors of Childhood and Adolescence
Arndt, C. A. S., & Crist, W. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907293410507 · Cited by 657
Lamoureux, F., Richard, P., Wittrant, Y., Battaglia, S., Pilet, P., Trichet, V., Blanchard, F., Gouin, F., Pitard, B., Heymann, D., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4130 · Cited by 181 · cited 4×
“Specific neutralization of RANKL has been achieved by either soluble RANK-IgG-Fc,((17)) recombinant OPG,((18)) or OPG-like peptidomimetic administrations((19)) in various preclinical models of osteolytic diseases and in osteosarcoma models.((20,21)) A fully human monoclonal antibody directed against RANKL (Denosumab,…”
BackgroundSelf-citationOry, B., Heymann, M., Kamijo, A., Gouin, F., Heymann, D., & Redini, F. (2005) · Cancer · doi:10.1002/cncr.21530 · Cited by 169
Self-citation
Cited by
Translational biology of osteosarcoma
Kansara, M., Teng, M. W., Smyth, M. J., & Thomas, D. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3838 · Cited by 1,294
The Osteosarcoma Microenvironment: A Complex but Targetable Ecosystem
Corre, I., Verrecchia, F., Crenn, V., Redini, F., & Trichet, V. (2020) · Cells · doi:10.3390/cells9040976 · Cited by 474
Self-citationLilienthal, I., & Herold, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186885 · Cited by 283
Heymann, M.-F., Lézot, F., & Heymann, D. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.10.011 · Cited by 233
Self-citationAvril, P., Le Nail, L.-R., Brennan, M. Á., Rosset, P., De Pinieux, G., Layrolle, P., Heymann, D., Perrot, P., & Trichet, V. (2016) · Journal of Bone Oncology · doi:10.1016/j.jbo.2015.11.002 · Cited by 38
Self-citation
Metadata
- Authors
- Rousseau, J., Escriou, V., Lamoureux, F., Brion, R., Chesneau, J., Battaglia, S., Amiaud, J., Scherman, D., Heymann, D., Rédini, F., & Trichet, V.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-06-28
- Volume
- 26
- Issue
- 10
- Pages
- 2452-2462
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W1991822063
- Cited by
- 40
- References
- 5
- FWCI
- 1.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models. https://app.cochat.ai/papers/10.1002/jbmr.455
- The paper
- Rousseau, J., Escriou, V., Lamoureux, F., Brion, R., Chesneau, J., Battaglia, S., Amiaud, J., Scherman, D., Heymann, D., Rédini, F., & Trichet, V. (2011). Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models. Journal of Bone and Mineral Research. https://doi.org/10.1002/jbmr.455
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.